Sanofi said on Tuesday that Yong-Jun Liu had been appointed as head of research with effect from April 1, reporting to Elias Zerhouni, the group’s president of global research and development.
Liu, a specialist in immunology with more than 250 published articles in leading academic journals, currently heads up research at AstraZeneca’s MedImmune biotechnology division, a position he has held since 2014.
Prior to that he led programmes at Baylor Research Institute and the MD Anderson Cancer Center, where he was founding director of the Cancer Immunology Research Institute.
His decision to leave AstraZeneca follows the exit last June of Briggs Morrison, the company’s former chief medical officer and head of late-stage drug development, and respiratory and inflammatory medicines head James Ward-Lilley.
AstraZeneca is going through a transition as older drugs lose patent protection and it invests heavily in new medicines, especially in the field of cancer immunotherapy.
It has a promising pipeline of experimental drugs but has also suffered some recent setbacks, including last week’s failure of its marketed heart drug Brilinta as a treatment for stroke patients and earlier disappointing results with a drug to treat lung and abdominal cancer mesothelioma.
Sanofi, meanwhile, is seeking to rejuvenate its early-stage pipeline and Zerhouni said Liu’s experience in immunology, oncology and translational medicine would be “vital assets” for this task.
Reporting by Ben Hirschler; editing by Jason Neely
Our Standards: The Thomson Reuters Trust Principles.